Osaic Holdings’s ProShares UltraShort NASDAQ Biotechnology BIS Stock Holding History

Osaic Holdings’s Portfolio BIS Stock Details BIS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-25	Closed	-$1.04K	–	7398
2023 Q2	$1.04K	Hold	25	–	–	﹤0.01%	6867
2023 Q1	$1.01K	Buy	+25	New	+$994	﹤0.01%	6945
2021 Q3	–	Sell	-549	Closed	-$20K	–	7179
2021 Q2	$20K	Buy	+549	New	+$23.3K	﹤0.01%	5651
2021 Q1	–	Sell	-313	Closed	-$15K	–	6800
2020 Q4	$15K	Buy	+313	New	+$17.1K	﹤0.01%	5319

Other funds holding BIS

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Osaic Holdings's BIS Position: Q3 2023 in Review

Osaic Holdings sold out of ProShares UltraShort NASDAQ Biotechnology (BIS) in Q3 2023, closing a stake of 25 shares — an estimated $1.04K sold.

Osaic Holdings first reported a position in BIS in Q4 2020 and held it in 4 quarters. The position peaked at $20K in Q2 2021. 6 funds tracked by Wall St. Rank hold BIS as of Q3 2023.

Osaic Holdings reported no remaining ProShares UltraShort NASDAQ Biotechnology position as of Q3 2023 after selling out during the quarter.
Osaic Holdings sold 25 ProShares UltraShort NASDAQ Biotechnology shares in Q3 2023, an estimated $1.04K.
Osaic Holdings first reported a position in ProShares UltraShort NASDAQ Biotechnology in Q4 2020 and held it in 4 quarters.
Osaic Holdings's ProShares UltraShort NASDAQ Biotechnology position peaked at $20K in Q2 2021.
6 funds tracked by Wall St. Rank held ProShares UltraShort NASDAQ Biotechnology as of Q3 2023.

Based on Osaic Holdings's 13F filing for Q3 2023, filed 13 Nov 2023.